Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

118.60 +5.47 (+4.84%)
Streaming Delayed Price Updated: 3:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biontech Se ADR

< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
Unveiling 12 Analyst Insights On BioNTech
Via Benzinga
Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell?
A clinical-trial failure for Pfizer and BioNTech means Moderna is leading the race to develop a combo shot for the flu and COVID-19. 
Via The Motley Fool
Why Pfizer Stock Slumped on Friday
Investors were cautiously pessimistic about the latest news coming out of the company's lab. 
Via The Motley Fool
Pfizer Slides Toward Sell Zone After BioNTech-Tied Covid/Flu Shot Misses Its Mark
The company is now considering whether it needs to change up the vaccine to pass muster. 
Via Investor's Business Daily
Pfizer, BioNTech's COVID-19/Flu Combo Vaccine Fails To Meet Key Goal In Late-Stage Study
Pfizer and BioNTech report Phase 3 results for their combined mRNA vaccine against influenza and COVID-19. The trial met one of two primary immunogenicity objectives. Adjustments are planned to improve... 
Via Benzinga
Exposures COVID-19
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
From Pfizer Inc.
Via Business Wire
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
From BioNTech SE
Via GlobeNewswire
Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows
COVID-19 vaccinations could lower the incidence of heart attacks and strokes, according to a new study by UK universities. The research shows a significant reduction in cardiovascular events among... 
Via Benzinga
Exposures COVID-19
Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows
A recent NIH study reveals no clear diagnostic test for Long Covid, highlighting ongoing challenges in identifying and treating the condition affecting millions of Americans. Researchers continue to... 
Via Benzinga
Exposures COVID-19
Navigating 12 Analyst Ratings For BioNTech
Via Benzinga
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?
Novavax Inc. (NASDAQ: NVAX) is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases. 
Via MarketBeat
Exposures COVID-19
3 Biotech Stocks With Promising Drug Pipelines: August 2024
The biotech stocks with promising pipelines could see shares soar if drugs in late-stage trials get FDA approval. 
Via InvestorPlace
Exposures Product Safety
This Cognizant Technology Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
BioNTech Se (BNTX) Q2 2024 Earnings Call Transcript
BNTX earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
US Stocks Trim Black Monday's Drops As Services Gauge Expands, Bond Gains Stall As Traders Reassess Fed Cuts: What's Driving Markets Monday?
Global markets are experiencing intense volatility, and while it seemed like a Black Monday for Wall Street was inevitable following a 13% overnight tumble of Japan’s Nikkei 225, stock indices are... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again.
Moderna sustained a rare downgrade on Monday following its guidance cut for the year. 
Via Investor's Business Daily
BNTX Stock Earnings: BioNTech Misses EPS, Misses Revenue for Q2 2024
BNTX stock results show that BioNTech missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
BioNTech posted a significant Q2 2024 loss of 807.8 million euros. Sales dropped to 128.7 million euros as the demand for COVID-19 vaccines shifted. R&D expenses rose due to late-stage oncology... 
Via Benzinga
Exposures COVID-19
Nasdaq, R2K Futures Tumble Over 4%, VIX Spikes Over 100%, Bitcoin Plunges Hard As Global Sell-Off Deepens Amid Recession Fears
The stock market is on track to gap-open sharply lower on Monday as negative sentiment seen in the final two sessions of last week has carried over into the new week. The index futures were all sharply... 
Via Benzinga
Topics Economy Stocks
Exposures Economy US Equities
BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
What's Going On With BioNTech (BNTX) Shares?
BioNTech shares are trading lower by 5.3% during Thursday's session. Vaccine stocks are down after Moderna cut its 2024 outlook due to weak EU sales and increased U.S. competition. 
Via Benzinga
Moderna Slashes Its Outlook On 'Very Low' European Sales Despite Quarterly Beat
Moderna delivered nearly double the sales analysts expected in the second quarter. 
Via Investor's Business Daily
BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma
From BioNTech SE
Via GlobeNewswire
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
Triastek will develop oral RNA therapeutics with Germany’s BioNTech based on its 3D printing technology. Triastek will receive a $10 million upfront payment and up to $1.2 billion in milestones, plus... 
Via Talk Markets
BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024
From BioNTech SE
Via GlobeNewswire
European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implications discussed. 
Via Benzinga
Exposures COVID-19
GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B
GSK and CureVac restructured their collaboration into a new licensing agreement, prioritizing mRNA vaccine development. GSK gains full control of vaccine candidates for influenza and COVID-19, while... 
Via Benzinga
Exposures COVID-19
London High Court Ruling Fuels Pfizer And Moderna Legal Dispute Over COVID-19 Vaccine Patents
Pfizer and Moderna continue their legal battle over COVID-19 vaccine patents following a mixed ruling by London's High Court, with potential appeals on the horizon and significant financial stakes... 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
The biotech sector (IBB) is trading just 3% away from its 52-week high and a significant resistance level, suggesting a potential breakout. 
Via MarketBeat
Topics ETFs
Exposures COVID-19
3 Nasdaq Stocks to Sell in July Before They Crash & Burn
These are three Nasdaq stocks to sell before their value plunges even further due to broader economic pressures. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.